Get the Stockscreener App
20.07
0.15%
0.03
Tandem Diabetes Care Inc stock is traded at $20.07, with a volume of 1.18M.
It is up +0.15% in the last 24 hours and down -13.04% over the past month.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
See More
Previous Close:
$20.04
Open:
$19.69
24h Volume:
1.18M
Relative Volume:
0.79
Market Cap:
$1.49B
Revenue:
$796.00M
Net Income/Loss:
$-136.49M
P/E Ratio:
-9.6029
EPS:
-2.09
Net Cash Flow:
$-64.24M
1W Performance:
-10.56%
1M Performance:
-13.04%
6M Performance:
-41.37%
1Y Performance:
-53.33%
1-Day Range:
$19.62
$20.78
1-Week Range:
$19.62
$22.56
52-Week Range:
$15.75
$48.24
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Name
Tandem Diabetes Care Inc
Sector
Industry
Phone
858-366-6900
Address
12400 HIGH BLUFF DRIVE, San Diego, CA
Compare TNDM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
20.07 | 1.49B | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
132.28 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
SYK
Stryker Corp
|
373.37 | 147.15B | 23.22B | 2.86B | 3.58B | 7.40 |
|
BSX
Boston Scientific Corp
|
101.73 | 146.97B | 17.55B | 2.03B | 2.72B | 1.37 |
|
MDT
Medtronic Plc
|
86.17 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
73.27 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Truist | Hold |
| Apr-10-25 | Initiated | Mizuho | Neutral |
| Mar-05-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Mar-03-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-28-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-02-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| Oct-04-24 | Initiated | Goldman | Neutral |
| Oct-02-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-22-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-08-24 | Initiated | Canaccord Genuity | Buy |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-29-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-25-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Mar-26-24 | Upgrade | Stifel | Hold → Buy |
| Aug-04-23 | Downgrade | Citigroup | Buy → Neutral |
| May-05-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-24-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-29-23 | Initiated | UBS | Neutral |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-15-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Aug-09-22 | Downgrade | Wells Fargo | Overweight → Underweight |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Underweight |
| Dec-15-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-20-20 | Initiated | Wells Fargo | Overweight |
| Jul-31-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-18-20 | Reiterated | Raymond James | Outperform |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Mar-23-20 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-06-20 | Initiated | Raymond James | Outperform |
| Feb-04-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-18-19 | Initiated | Guggenheim | Buy |
| Oct-04-19 | Upgrade | UBS | Neutral → Buy |
| May-17-19 | Reiterated | BofA/Merrill | Neutral |
| May-13-19 | Initiated | SVB Leerink | Outperform |
| Mar-08-19 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-19 | Reiterated | BofA/Merrill | Neutral |
| Feb-27-19 | Reiterated | Lake Street | Buy |
| Nov-21-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-26-18 | Reiterated | Dougherty & Company | Buy |
| Sep-26-18 | Reiterated | Piper Jaffray | Overweight |
View All
Tandem Diabetes Care Inc Stock (TNDM) Latest News
How To Trade (TNDM) - news.stocktradersdaily.com
Digital Diabetes Management Market 2025Growth in Apps, - openPR.com
Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities - FinancialContent
What Does Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Share Price Indicate? - Yahoo Finance
Abbott, Tandem Diabetes Care Partner For Glucose-Ketone Sensor for Diabetes Management - Insider Monkey
Tandem Diabetes Care’s SWOT analysis: stock faces growth hurdles amid market shifts - Investing.com
TNDM: Truist Securities Initiates Coverage with Hold Rating | TN - GuruFocus
10 Best Stocks to Buy For Beginners Now - Insider Monkey
Truist bullish on diabetes companies citing potential market growth - Seeking Alpha
Truist initiates Tandem Diabetes Care stock with hold rating By Investing.com - Investing.com Canada
Tandem Diabetes (TNDM) Receives Hold Rating from Truist | TNDM S - GuruFocus
Truist Initiates Tandem Diabetes Care at Hold With $24 Price Target - marketscreener.com
Abbott Laboratories (NYSE:ABT) Partners With Tandem To Develop Dual Sensor Diabetes Solutions - simplywall.st
Tandem, Abbott team on insulin delivery with glucose-ketone sensor - MedTech Dive
Abbott to pair glucose-ketone sensor with Tandem's insulin pumps - Modern Healthcare
Tandem Diabetes Care Announces Agreement with Abbott for Integration of Automated Insulin Delivery Systems with Future Glucose-Ketone Sensor - marketscreener.com
Tandem Diabetes Inks Deal With Abbott For New Diabetes Solutions: Retail Sentiment Stays Subdued By Stocktwits - Investing.com India
Tandem Diabetes Inks Deal With Abbott For New Diabetes Solutions: Retail Sentiment Stays Subdued - Asianet Newsable
Diabetes partnerships abound ahead of ADA - BioWorld MedTech
Tandem Diabetes at Goldman Sachs Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Transcript : Tandem Diabetes Care, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08 - marketscreener.com
Tandem Diabetes (TNDM) Partners with Abbott for Innovative Diabe - GuruFocus
Tandem, Abbott in deal to combine insulin delivery with glucose-ketone sensor - Seeking Alpha
Tandem Diabetes Care Announces Agreement With Abbott For Integration Of Automated Insulin Delivery Systems With Future Glucose-Ketone Sensor - marketscreener.com
Tandem Diabetes, Abbott to Merge Insulin Pump with Future Glucose-Ketone Sensor - Medical Product Outsourcing
Abbott (ABT) Partners with Tandem Diabetes for Advanced Diabetes Management Solutions | ABT Stock News - GuruFocus
Tandem Diabetes Care Announces Agreement with Abbott for Integration of Automated Insulin Delivery Systems with Future Glucose-Ketone Sensor | TNDM Stock News - GuruFocus
3 Reasons to Sell TNDM and 1 Stock to Buy Instead - Yahoo Finance
Transcript : Tandem Diabetes Care, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 03 - marketscreener.com
Tandem to pay Roche $36M in patent dispute settlement - MSN
Tandem Diabetes Care: A Barbell Bet On A High-Stakes Turnaround (NASDAQ:TNDM) - Seeking Alpha
(TNDM) Long Term Investment Analysis - news.stocktradersdaily.com
Tandem Diabetes at Jefferies: Expanding Market Horizons By Investing.com - Investing.com Canada
How the Non-Invasive Drug Delivery Device Market Will Evolve - openPR.com
Do You Believe in the Long-Term Growth Potential of Tandem Diabetes Care (TNDM)? - Insider Monkey
Roche settles UPC dispute over insulin distribution technology - JUVE Patent
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges - Benzinga
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Average Recommendation of “Hold” from Analysts - Defense World
Tandem Diabetes Care Inc (TNDM) Shares Gap Down to $20.62 on May 30 - GuruFocus
Tandem Diabetes Care (TNDM) Up 6.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Contrasting Tandem Diabetes Care (NASDAQ:TNDM) and PolyPid (NASDAQ:PYPD) - Defense World
Cetera Investment Advisers Acquires 981 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Reflecting On Healthcare Technology Stocks’ Q1 Earnings: Tandem Diabetes (NASDAQ:TNDM) - Yahoo Finance
Tandem Diabetes and Roche Reach a Patent Settlement - MSN
How the (TNDM) price action is used to our Advantage - news.stocktradersdaily.com
Tandem Diabetes, Roche enter patent settlement agreement - Yahoo Finance
Tandem Diabetes Care (TNDM) Settles Patent Dispute with Roche - GuruFocus
Should Tandem Diabetes Stock Stay in Your Portfolio Now? - MSN
Tandem Diabetes To Pay Roche $36 Mln To Settle Patent Infringement Claim - Nasdaq
Tandem Diabetes Agrees to Pay Roche $36 Million in Patent Infringement Deal - marketscreener.com
Tandem Diabetes Care Inc Stock (TNDM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):